Milvexian- ACS study
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group, event-driven, superiority, group sequential study to evaluate the efficacy and safety of milvexian in participants enrolled within 7 days of an Acute Coronary Syndrome. Participants will receive either milvexian/ placebo on a background of standard-of-care antiplatelet therapy. The total study duration is approximately 3.5 years.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
09 Mar 2024.
Study ID: 853536
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com